Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.

James J HardingRichard K DoAmin YaqubieAnn CleverlyYumin ZhaoIvelina GueorguievaMichael LahnKarim A BenhadjiRobin K KelleyGhassan K Abou-Alfa

Published in: Cancer medicine (2021)

Combination therapy was safe and tolerable and displayed favorable PK. The MTD was established at galunisertib at 150 mg orally twice a day and ramucirumab 8 mg/kg intravenously every 2 weeks. The results do not support the preclinical hypothesis that blocking TGFβ signaling enhances efficacy of VEGF-targeted therapy; thus further clinical development was halted for the combination of galunisertib and ramucirumab.

Keyphrases

combination therapy
endothelial cells
transforming growth factor
vascular endothelial growth factor
epithelial mesenchymal transition
bone marrow
gestational age
signaling pathway